What is Summit Therapeutics known for?
Summit Therapeutics is a prominent clinical-stage biopharmaceutical enterprise recognized globally for its intensive focus on oncology and immuno-oncology therapeutic development. The company achieved widespread recognition and major market interest through its licensing agreement for ivonescimab (AK112), an innovative bispecific antibody designed to target both programmed cell death protein 1 and vascular endothelial growth factor. This flagship clinical asset is being evaluated in advanced trials for treating non-small cell lung cancer and other critical oncological indications.
Related FAQs
Analysts tracking Summit Therapeutics Inc. (SMMT) maintain a strong consensus "Buy" rating, supported by high institutional enthusiasm for its clinical-stage oncology pipeline and innovative bispecific antibody developments like ivonescimab.
Institutional analysts tracking Summit Therapeutics Inc. (SMMT) project a consensus 12-month average price target averaging around $28.15 to $28.39 per share. Individual institutional forecasts span from a low estimate of approximately $9.
Summit Therapeutics Inc. (SMMT) carries median 12-month analyst price targets clustering around $28.00 to $34.00 per share, reflecting significant upside potential from clinical-stage valuations.
The stock ticker SMMT represents the corporate equity shares of Summit Therapeutics Inc., which is a clinical-stage biopharmaceutical enterprise dedicated to discovering, developing, and commercializing novel oncology medicines.
Sun Life Financial Inc. continues to exist and operate as a preeminent global financial services organization, recognized as a leading international provider of insurance, wealth accumulation, and asset management solutions.
Summit Therapeutics Inc. (SMMT) is a clinical-stage biopharmaceutical enterprise focused on discovering, developing, and commercializing novel oncology medicines, anchored by its flagship bispecific antibody ivonescimab.
Wall Street equity research analysts covering Summit Therapeutics plc (SMMT) establish a consensus 12-month average price target hovering around $28.06 to $28.38 per share.
Summit Therapeutics Inc. (NASDAQ: SMMT) trades at $13.04 per share, commanding a multi-billion-dollar market capitalization of roughly $10.40 billion.
Summit Therapeutics Inc, trading under the ticker SMMT, represents a clinical-stage biopharmaceutical equity that has garnered intense market interest due to its promising oncology pipeline developments, particularly novel bispecific antibodies targe...
Take-Two Interactive Software (TTWO) exhibits strong structural upside potential, with Wall Street analyst consensus projections and medium-term price targets clustering around elevated valuation tiers.
Snap-on Tools provides a famous limited lifetime warranty covering hand tools and select mechanical equipment against manufacturing defects in materials and workmanship throughout the functional lifespan of the product.
Assessing whether Summit Therapeutics is Shariah compliant involves running its underlying financial data and business activities through established Islamic finance screening filters.
Supernus Pharmaceuticals has experienced fluctuating financial profitability, frequently alternating between periods of net losses and positive operating earnings depending on quarterly commercial product sales and collaboration milestones.
Sun Communities, Inc. is a self-administered real estate investment trust (REIT) that acquires, operates, and develops manufactured housing communities, recreational vehicle (RV) resorts, and marinas primarily across North America.
Workplace evaluations for Summit Therapeutics indicate that it is an innovation-focused, dynamic clinical-stage biopharmaceutical enterprise offering competitive compensation packages, specialized scientific roles, and opportunities to contribute to ...
Determining whether Summit Therapeutics stock is an appropriate purchase depends heavily on an investor's tolerance for high-growth, high-risk life sciences equities.
Assessing the share price volatility of Teledyne Technologies Incorporated—a major provider of sophisticated instrumentation, digital imaging products, aerospace and defense electronics, and engineered systems—reveals a low to moderate volatility pro...
Summit Therapeutics is an innovative, clinical-stage biopharmaceutical enterprise that has garnered substantial industry attention for its promising oncology pipeline, most notably its flagship bispecific antibody drug candidate, ivonescimab.